{
    "xml": "<topic id=\"PHP3884\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/telaprevir\" basename=\"telaprevir\" title=\"TELAPREVIR\">\n<title>TELAPREVIR</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1216\" namespace=\"/interactions/list-of-drug-interactions/antivirals/telaprevir\">Telaprevir</xref>\n</p>\n<data name=\"vtmid\">704466001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_321881277\" title=\"Protease inhibitors (hepatitis)\">Protease inhibitors (hepatitis)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP71772\" outputclass=\"indicationsAndDose\" rev=\"1.13\" parent=\"/drugs/telaprevir\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1.125&#8239;g every 12&#8239;hours, alternatively 750&#8239;mg every 8&#8239;hours, for duration of treatment consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71814\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/telaprevir\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Bradycardia</ph>; <ph outputclass=\"caution\">congenital or family history of QT interval prolongation</ph>; <ph outputclass=\"caution\">electrolyte disturbances</ph>; <ph outputclass=\"caution\">family history of sudden death</ph>; <ph outputclass=\"caution\">heart failure with reduced left ventricular ejection fraction</ph>; <ph outputclass=\"caution\">hypoalbuminaemia</ph>; <ph outputclass=\"caution\">low platelets</ph>; <ph outputclass=\"caution\">prolongation of QT interval</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Low platelets or hypoalbuminaemia</p>\n<p>Not recommended in patients with low platelets or hypoalbuminaemia&#8212;if initiated in these patients monitor closely for signs of infection, worsening liver impairment, and anaemia (increased risk of severe morbidity and mortality).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71764\" outputclass=\"interactions\" rev=\"1.13\" parent=\"/drugs/telaprevir\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (telaprevir).</p>\n<p>Caution in concomitant use with other drugs known to prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71716\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/telaprevir\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">anal fissure (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">diarrhoea (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">eczema (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">haemorrhoids (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">hyperbilirubinaemia (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">hypokalaemia (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">hypothyroidism (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">lymphopenia (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">nausea (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">peripheral oedema (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">pruritus (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">rash (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">syncope (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">taste disturbances (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">vomiting (in combination with ribavirin and peginterferon alfa)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gout (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">proctitis (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">retinopathy (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">urticaria (in combination with ribavirin and peginterferon alfa)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Stevens-Johnson syndrome (in combination with ribavirin and peginterferon alfa)</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis (in combination with ribavirin and peginterferon alfa)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Rash</p>\n<p>Rash occurs very commonly. If rash mild or moderate, may continue without interruption, but monitor for deterioration. If moderate rash deteriorates, consider permanent discontinuation of telaprevir; if rash does not improve within 7 days of discontinuation, suspend ribavirin. If severe rash or if rash accompanied by blistering or mucosal ulceration, discontinue telaprevir permanently; if rash does not improve within 7 days of discontinuation, consider discontinuation of ribavirin and peginterferon alfa. If serious rash, or if severe rash deteriorates, or if rash accompanied by systemic symptoms, discontinue telaprevir, ribavirin, and peginterferon alfa permanently.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71810\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/telaprevir\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effectiveness of hormonal contraceptives reduced during treatment and for 2 months after stopping telaprevir&#8212;effective non-hormonal methods of contraception necessary during this time.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71761\" outputclass=\"pregnancy\" parent=\"/drugs/telaprevir\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71833\" outputclass=\"breastFeeding\" parent=\"/drugs/telaprevir\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71779\" outputclass=\"hepaticImpairment\" parent=\"/drugs/telaprevir\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid in moderate to severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71685\" outputclass=\"monitoringRequirements\" parent=\"/drugs/telaprevir\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor full blood count, platelets, electrolytes, serum creatinine, uric acid, and liver and thyroid function tests before starting treatment and then on weeks 2, 4, 8, and 12 of treatment, then as indicated clinically.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58725\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/telaprevir\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dispense in original container (contains desiccant).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71753\" outputclass=\"patientAndCarerAdvice\" rev=\"1.8\" parent=\"/drugs/telaprevir\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p>If a dose is more than 6 hours late with the 12 hourly regimen (or more than 4 hours late with the 8 hourly regimen), the missed dose should not be taken and the next dose should be taken at the normal time.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients should be told to seek immediate medical attention if a rash develops or if an existing rash worsens.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71666\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/telaprevir\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA252</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Telaprevir for chronic hepatitis C infection of genotype 1 (April 2012)</p>\r\n<p>Telaprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease: </p>\r\n<ul>\r\n<li>who have not been treated previously;</li>\r\n<li>in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA252\">www.nice.org.uk/TA252</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3884-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/telaprevir\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76644\" title=\"Tablet\" namespace=\"/drugs/telaprevir/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78120\" namespace=\"/treatment-summaries/respiratory-syncytial-virus\" title=\"Respiratory syncytial virus\" count=\"1\" rel=\"backlink\">Respiratory syncytial virus</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78240\" namespace=\"/treatment-summaries/hepatitis\" title=\"Hepatitis\" count=\"4\" rel=\"backlink\">Hepatitis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1216\" namespace=\"/interactions/list-of-drug-interactions/antivirals/telaprevir\" title=\"Telaprevir\" count=\"1\" rel=\"link\">Telaprevir</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76644\" namespace=\"/drugs/telaprevir/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP3884",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/telaprevir",
    "basename": "telaprevir",
    "title": "TELAPREVIR",
    "interactants": [
        {
            "id": "bnf_int_1216",
            "label": "Telaprevir"
        }
    ],
    "vtmid": "704466001",
    "drugClassification": [
        "Protease inhibitors (hepatitis)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease",
                        "html": "In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1.125 g every 12 hours, alternatively 750 mg every 8 hours, for duration of treatment consult product literature.",
                        "html": "<p>1.125&#8239;g every 12&#8239;hours, alternatively 750&#8239;mg every 8&#8239;hours, for duration of treatment consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Bradycardia",
                "html": "Bradycardia"
            },
            {
                "type": "cautions",
                "textContent": "congenital or family history of QT interval prolongation",
                "html": "congenital or family history of QT interval prolongation"
            },
            {
                "type": "cautions",
                "textContent": "electrolyte disturbances",
                "html": "electrolyte disturbances"
            },
            {
                "type": "cautions",
                "textContent": "family history of sudden death",
                "html": "family history of sudden death"
            },
            {
                "type": "cautions",
                "textContent": "heart failure with reduced left ventricular ejection fraction",
                "html": "heart failure with reduced left ventricular ejection fraction"
            },
            {
                "type": "cautions",
                "textContent": "hypoalbuminaemia",
                "html": "hypoalbuminaemia"
            },
            {
                "type": "cautions",
                "textContent": "low platelets",
                "html": "low platelets"
            },
            {
                "type": "cautions",
                "textContent": "prolongation of QT interval",
                "html": "prolongation of QT interval"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Low platelets or hypoalbuminaemia",
                "textContent": "Not recommended in patients with low platelets or hypoalbuminaemia&#8212;if initiated in these patients monitor closely for signs of infection, worsening liver impairment, and anaemia (increased risk of severe morbidity and mortality).",
                "html": "<p>Not recommended in patients with low platelets or hypoalbuminaemia&#8212;if initiated in these patients monitor closely for signs of infection, worsening liver impairment, and anaemia (increased risk of severe morbidity and mortality).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (telaprevir).\n\nCaution in concomitant use with other drugs known to prolong QT interval.",
                "html": "<p>Appendix 1 (telaprevir).</p><p>Caution in concomitant use with other drugs known to prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia (in combination with ribavirin and peginterferon alfa)",
                        "html": "Anaemia (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anal fissure (in combination with ribavirin and peginterferon alfa)",
                        "html": "anal fissure (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea (in combination with ribavirin and peginterferon alfa)",
                        "html": "diarrhoea (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eczema (in combination with ribavirin and peginterferon alfa)",
                        "html": "eczema (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhoids (in combination with ribavirin and peginterferon alfa)",
                        "html": "haemorrhoids (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperbilirubinaemia (in combination with ribavirin and peginterferon alfa)",
                        "html": "hyperbilirubinaemia (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperuricaemia (in combination with ribavirin and peginterferon alfa)",
                        "html": "hyperuricaemia (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypokalaemia (in combination with ribavirin and peginterferon alfa)",
                        "html": "hypokalaemia (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypothyroidism (in combination with ribavirin and peginterferon alfa)",
                        "html": "hypothyroidism (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "lymphopenia (in combination with ribavirin and peginterferon alfa)",
                        "html": "lymphopenia (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea (in combination with ribavirin and peginterferon alfa)",
                        "html": "nausea (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema (in combination with ribavirin and peginterferon alfa)",
                        "html": "peripheral oedema (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus (in combination with ribavirin and peginterferon alfa)",
                        "html": "pruritus (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash (in combination with ribavirin and peginterferon alfa)",
                        "html": "rash (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "syncope (in combination with ribavirin and peginterferon alfa)",
                        "html": "syncope (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "taste disturbances (in combination with ribavirin and peginterferon alfa)",
                        "html": "taste disturbances (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "thrombocytopenia (in combination with ribavirin and peginterferon alfa)",
                        "html": "thrombocytopenia (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting (in combination with ribavirin and peginterferon alfa)",
                        "html": "vomiting (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Gout (in combination with ribavirin and peginterferon alfa)",
                        "html": "Gout (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "proctitis (in combination with ribavirin and peginterferon alfa)",
                        "html": "proctitis (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "retinopathy (in combination with ribavirin and peginterferon alfa)",
                        "html": "retinopathy (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "urticaria (in combination with ribavirin and peginterferon alfa)",
                        "html": "urticaria (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Stevens-Johnson syndrome (in combination with ribavirin and peginterferon alfa)",
                        "html": "Stevens-Johnson syndrome (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "toxic epidermal necrolysis (in combination with ribavirin and peginterferon alfa)",
                        "html": "toxic epidermal necrolysis (in combination with ribavirin and peginterferon alfa)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Rash",
                "textContent": "Rash occurs very commonly. If rash mild or moderate, may continue without interruption, but monitor for deterioration. If moderate rash deteriorates, consider permanent discontinuation of telaprevir; if rash does not improve within 7 days of discontinuation, suspend ribavirin. If severe rash or if rash accompanied by blistering or mucosal ulceration, discontinue telaprevir permanently; if rash does not improve within 7 days of discontinuation, consider discontinuation of ribavirin and peginterferon alfa. If serious rash, or if severe rash deteriorates, or if rash accompanied by systemic symptoms, discontinue telaprevir, ribavirin, and peginterferon alfa permanently.",
                "html": "<p>Rash occurs very commonly. If rash mild or moderate, may continue without interruption, but monitor for deterioration. If moderate rash deteriorates, consider permanent discontinuation of telaprevir; if rash does not improve within 7 days of discontinuation, suspend ribavirin. If severe rash or if rash accompanied by blistering or mucosal ulceration, discontinue telaprevir permanently; if rash does not improve within 7 days of discontinuation, consider discontinuation of ribavirin and peginterferon alfa. If serious rash, or if severe rash deteriorates, or if rash accompanied by systemic symptoms, discontinue telaprevir, ribavirin, and peginterferon alfa permanently.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effectiveness of hormonal contraceptives reduced during treatment and for 2 months after stopping telaprevir&#8212;effective non-hormonal methods of contraception necessary during this time.",
                "html": "<p>Effectiveness of hormonal contraceptives reduced during treatment and for 2 months after stopping telaprevir&#8212;effective non-hormonal methods of contraception necessary during this time.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid.",
                "html": "<p>Manufacturer advises avoid.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid in moderate to severe impairment.",
                "html": "<p>Manufacturer advises avoid in moderate to severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor full blood count, platelets, electrolytes, serum creatinine, uric acid, and liver and thyroid function tests before starting treatment and then on weeks 2, 4, 8, and 12 of treatment, then as indicated clinically.",
                "html": "<p>Monitor full blood count, platelets, electrolytes, serum creatinine, uric acid, and liver and thyroid function tests before starting treatment and then on weeks 2, 4, 8, and 12 of treatment, then as indicated clinically.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Dispense in original container (contains desiccant).",
                "html": "<p>Dispense in original container (contains desiccant).</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "textContent": "If a dose is more than 6 hours late with the 12 hourly regimen (or more than 4 hours late with the 8 hourly regimen), the missed dose should not be taken and the next dose should be taken at the normal time.",
                "html": "<p>If a dose is more than 6 hours late with the 12 hourly regimen (or more than 4 hours late with the 8 hourly regimen), the missed dose should not be taken and the next dose should be taken at the normal time.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients should be told to seek immediate medical attention if a rash develops or if an existing rash worsens.",
                "html": "<p>Patients should be told to seek immediate medical attention if a rash develops or if an existing rash worsens.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA252",
                        "label": "www.nice.org.uk/TA252"
                    }
                ],
                "fundingIdentifier": "NICE TA252",
                "textContent": "Telaprevir for chronic hepatitis C infection of genotype 1 (April 2012) Telaprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease: who have not been treated previously; in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed.\n\nwww.nice.org.uk/TA252",
                "html": "<p outputclass=\"title\">Telaprevir for chronic hepatitis C infection of genotype 1 (April 2012)</p> <p>Telaprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease: </p> <ul> <li>who have not been treated previously;</li> <li>in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA252\">www.nice.org.uk/TA252</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76644",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78120",
                "label": "Respiratory syncytial virus",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78240",
                "label": "Hepatitis",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1216",
                "label": "Telaprevir",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76644",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}